Litcius/Paper detail

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Maria Gavriatopoulou, Albert Oriol, Neil Rabin, Ajay Nooka, Ming Qi, Meral Beksac, Andrzej Jakubowiak, Bifeng Ding, Anita Zahlten-Kumeli, Akeem Yusuf, Meletios Dimopoulos

2021The Lancet Oncology160 citationsDOI

Topics & Concepts

DaratumumabCarfilzomibMedicineOncologyInternal medicineMultiple myelomaRefractory (planetary science)DexamethasonePhases of clinical researchClinical trialPhase (matter)MEDLINEChemotherapyMultiple Myeloma Research and TreatmentsCancer Mechanisms and TherapyBioactive Compounds in Plants
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study | Litcius